` SANN (Santhera Pharmaceuticals Holding AG) vs Swiss Market Index Comparison - Alpha Spread

S
SANN
vs
S
Swiss Market Index

Over the past 12 months, SANN has outperformed Swiss Market Index, delivering a return of +12% compared to the Swiss Market Index's +5% growth.

Stocks Performance
SANN vs Swiss Market Index

Loading
SANN
Swiss Market Index
Add Stock
www.alphaspread.com

Performance Gap
SANN vs Swiss Market Index

Loading
SANN
Swiss Market Index
Difference
www.alphaspread.com

Performance By Year
SANN vs Swiss Market Index

Loading
SANN
Swiss Market Index
Add Stock

Competitors Performance
Santhera Pharmaceuticals Holding AG vs Peers

Swiss Market Index
SANN
ABBV
AMGN
GILD
VRTX
Add Stock

Santhera Pharmaceuticals Holding AG
Glance View

Market Cap
140m CHF
Industry
Biotechnology

Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

SANN Intrinsic Value
43.46 CHF
Undervaluation 76%
Intrinsic Value
Price
S
Back to Top